DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Hexalen (Altretamine) - Summary

 
 



WARNINGS

  1. HEXALEN® capsules should only be given under the supervision of a physician experienced in the use of antineoplastic agents.
  2. Peripheral blood counts should be monitored at least monthly, prior to the initiation of each course of HEXALEN® capsules, and as clinically indicated (see Adverse Reactions).
  3. Because of the possibility of HEXALEN® capsules-related neurotoxicity, neurologic examination should be performed regularly during HEXALEN® capsules administration (see Adverse Reactions).
 

HEXALEN SUMMARY

HEXALEN®
(ALTRETAMINE) CAPSULES 50 mg

HEXALEN (altretamine), is a synthetic cytotoxic antineoplastic s-triazine derivative. HEXALEN capsules contain 50 mg of altretamine for oral administration. Inert ingredients include lactose, anhydrous and calcium stearate.

HEXALEN is indicated for use as a single agent in the palliative treatment of patients with persistent or recurrent ovarian cancer following first-line therapy with a cisplatin and/or alkylating agent-based combination.


See all Hexalen indications & dosage >>

NEWS HIGHLIGHTS

Media Articles Related to Hexalen (Altretamine)

Improved survival of ovarian cancer patients receiving treatment guided by comprehensive tumour profiling
Source: Medical Devices / Diagnostics News From Medical News Today [2014.09.12]
Data from an ovarian cancer registry presented at the European Society for Gynaecological Oncology (ESGO) annual meeting reinforce comprehensive tumour profiling as a 'game changer' for oncologists.

Ovarian cancer oncogene found in 'junk DNA'
Source: Genetics News From Medical News Today [2014.09.09]
Over the years researchers have made tremendous strides in the understanding and treatment of cancer by searching genomes for links between genetic alterations and disease.

New blood test could offer more tailored treatment of ovarian cancer
Source: Medical Devices / Diagnostics News From Medical News Today [2014.09.08]
A new blood test allowing doctors to predict which ovarian cancer patients will respond to particular types of treatment is a step closer following a new study by Manchester scientists.

Why are many women at risk of ovarian cancer not aware of it?
Source: Breast Cancer News From Medical News Today [2014.09.04]
The color teal in September represents Ovarian Cancer Awareness Month. This may be the most difficult women's cancer to detect and treat, yet many women are unaware of the risks.

Pair of Pills Shows Promise for Recurrent Ovarian Cancer
Source: MedicineNet Ovarian Cancer Specialty [2014.06.02]
Title: Pair of Pills Shows Promise for Recurrent Ovarian Cancer
Category: Health News
Created: 5/31/2014 9:38:00 AM
Last Editorial Review: 6/2/2014 12:00:00 AM

more news >>

Published Studies Related to Hexalen (Altretamine)

The bioavailability of three altretamine formulations. [1989.12.15]
The bioavailability of two altretamine preparations was studied in a randomized cross-over design. The two preparations were compared with a third in a parallel design... The in vivo data showed a trend to differences in bioavailability.

Synergy of irofulven in combination with other DNA damaging agents: synergistic interaction with altretamine, alkylating, and platinum-derived agents in the MV522 lung tumor model. [2008.12]
PURPOSE: Irofulven (MGI 114, NSC 683863) is a semisynthetic derivative of illudin S, a natural product present in the Omphalotus illudins (Jack O'Lantern) mushroom. This novel agent produces DNA damage, that in contrast to other agents, is predominately ignored by the global genome repair pathway of the nucleotide excision repair (NER)(2) system. The aim of this study was to determine the antitumor activity of irofulven when administered in combination with 44 different DNA damaging agents, whose damage is in general detected and repaired by the genome repair pathway... CONCLUSION: These results indicate that the antitumor activity of irofulven is enhanced when combined with platinum-derived agents, altretamine, and select alkylating agents such as melphalan or chlorambucil. A common factor between these agents appears to be the production of intrastrand DNA crosslinks. The synergistic interaction between irofulven and other agents may stem from the nucleotide excision repair system being selectively overwhelmed at two distinct points in the pathway, resulting in prolonged stalling of transcription forks, and subsequent initiation of apoptosis.

Long-term follow-up of a phase II trial of oral altretamine for consolidation of clinical complete remission in women with stage III epithelial ovarian cancer in the Southwest Oncology Group. [2004.03]
OBJECTIVE: This report provides follow-up progression-free survival (PFS) and median survival data for women who achieved clinical complete remission (cCR) from stage III ovarian cancer after first-line therapy and were treated with altretamine consolidation therapy... CONCLUSIONS: Consolidation therapy with oral altretamine was generally well tolerated and associated with prolonged progression-free and overall survival in the Phase II setting.

Oral altretamine used as salvage therapy in recurrent ovarian cancer. [2004.01]
CONCLUSION: Outpatient-administered oral altretamine can provide a prolonged disease-free interval with minimal toxicity.

Altretamine (hexamethylmelamine) in the treatment of platinum-resistant ovarian cancer: a phase II study. [2003.02]
OBJECTIVE: To evaluate the activity of oral Altretamine in women with epithelial ovarian carcinoma who responded (PR or CR) to first line chemotherapy but relapsed within 6 months. The protocol was later amended to include patients with relapse within 12 months... CONCLUSION: Altretamine should not be chosen as standard treatment in patients with platinum-resistant recurrent ovarian cancer. However, Altretamine represents a useful alternative in patients who prefer oral treatment or when socioeconomic considerations are an important issue.

more studies >>

Clinical Trials Related to Hexalen (Altretamine)

Recombinant Albumin Fusion Protein sEphB4-HSA in Treating Patients With Metastatic or Recurrent Solid Tumors [Recruiting]
This study is about an experimental drug called sEphB4-HSA (recombinant albumin fusion protein sEphB4-HSA). This research study will be the first time sEphB4-HSA is given to people. sEphB4-HSA prevents tumor cells from multiplying and blocks several compounds that promote the growth of blood vessels that bring nutrients to the tumor. sEphB4-HSA has shrunk colon, lung, breast, glioma, melanoma, prostate and Kaposi's sarcoma tumors in mice

A Prospective Validation Study of Albumin Kinetics With Tracer 123 I-HSA [Recruiting]
This is a prospective, validation study of a extempore made tracer compared with a commercial. Studies with tracer have no medical effects but are used for studying human physiology, in this case pharmacokinetic variables of endogenous albumin distribution and turnover at different levels of inflammation.

1. Primary Objective:

- Do the extempore made tracer 123-iodine labeled albumin an commercially manufactured

SERALB-125 give identical values of calculated blood plasma volume and capillary leakage measured as transcapillary escape rate of albumin?

2. Secondary Objective:

- How do three different measures of albumin turnover correlate in volunteers?

- How do the pharmacokinetic parameters of endogenous albumin vary between the three

study groups?

Altretamine and Etoposide in Treating Patients With HIV-Related Cancer [Completed]
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.

PURPOSE: Phase I trial to study the effectiveness of altretamine plus etoposide in treating patients with HIV-related cancer.

Acute Neurocardiogenic Injury After Subarachnoid Hemorrhage. [Recruiting]
The aim of this study is to describe acute neurocardiogenic injury after subarachnoid hemorrhage assessed with cardiac 123I-MIBG scintigraphy and 18F-FDG PET/CT during the first week and the first six months after SAH.

The study hypothesis is that the evolution of the cardiac disturbances follows the clinical evolution.

Investigating the Relationships Among Illness Cognition, Social Support, Stress, and Emotional Reactions of Infertile Patients [Recruiting]

more trials >>


Page last updated: 2014-09-12

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2014